Synthorx to Present at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
May 15, 2019 17:15 ET
|
Synthorx, Inc.
SAN DIEGO, May 15, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company discovering and developing optimized biologics for cancer and autoimmune disorders, today announced...
Synthorx Reports First Quarter Financial Results
April 30, 2019 16:05 ET
|
Synthorx, Inc.
SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop...
Synthorx to Present at H.C. Wainwright Global Life Sciences Conference in London
April 02, 2019 08:00 ET
|
Synthorx, Inc.
SAN DIEGO, April 02, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop...
Synthorx to Present at the American Association of Cancer Research (AACR) Annual Meeting 2019
March 19, 2019 08:00 ET
|
Synthorx, Inc.
SAN DIEGO, March 19, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop...
Synthorx Reports Fourth Quarter and Full Year 2018 Financial Results
March 12, 2019 16:05 ET
|
Synthorx, Inc.
Company Positioned for Upcoming 2019 Milestones After Successful IPO Raising $150.7 Million in Gross Proceeds Presented Preclinical Safety and Anti-Tumor Data on Lead Product Candidate THOR-707 at...
Synthorx to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy
March 12, 2019 08:00 ET
|
Synthorx, Inc.
SAN DIEGO, March 12, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop...
Synthorx to Present at the 8th Annual SVB Leerink Global Healthcare Conference
February 21, 2019 16:05 ET
|
Synthorx, Inc.
SAN DIEGO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop...
Synthorx Appoints Andrew Powell, J.D., to its Board of Directors
December 20, 2018 08:00 ET
|
Synthorx, Inc.
SAN DIEGO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop...
Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 12, 2018 16:05 ET
|
Synthorx, Inc.
SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop...
Synthorx Announces Pricing of Initial Public Offering
December 06, 2018 21:15 ET
|
Synthorx, Inc.
SAN DIEGO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop...